Duquesne Family Office’s Biogen BIIB Stock Holding History

Duquesne Family Office’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-109,400	Closed	-$34.9M	–	25
2017 Q4	$34.9M	Buy	109,400 +61,400	+128%	+$19.7M	1.76%	14
2017 Q3	$15M	Buy	+48,000	New	+$14.2M	0.68%	30
2015 Q2	–	Sell	-175,000	Closed	-$73.9M	–	31
2015 Q1	$73.9M	Sell	175,000 -184,400	-51%	-$72.7M	9.39%	2
2014 Q4	$122M	Buy	359,400 +255,600	+246%	+$82.7M	11.96%	1
2014 Q3	$34.3M	Hold	103,800	–	–	4.21%	6
2014 Q2	$32.7M	Buy	+103,800	New	+$31.2M	2.34%	10
2014 Q1	–	Sell	-91,500	Closed	-$25.6M	–	25
2013 Q4	$25.6M	Hold	91,500	–	–	1.7%	23
2013 Q3	$22M	Hold	91,500	–	–	2.61%	14
2013 Q2	$19.7M	Buy	+91,500	New	+$19.6M	2.92%	11

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Duquesne Family Office's BIIB Position: Q1 2018 in Review

Duquesne Family Office sold out of Biogen (BIIB) in Q1 2018, closing a stake of 109,400 shares — an estimated $34.9M sold.

Duquesne Family Office first reported a position in BIIB in Q2 2013 and held it in 9 quarters. The position peaked at $122M in Q4 2014. 1,102 funds tracked by Wall St. Rank hold BIIB as of Q1 2018.

Duquesne Family Office reported no remaining Biogen position as of Q1 2018 after selling out during the quarter.
Duquesne Family Office sold 109,400 Biogen shares in Q1 2018, an estimated $34.9M.
Duquesne Family Office first reported a position in Biogen in Q2 2013 and held it in 9 quarters.
Duquesne Family Office's Biogen position peaked at $122M in Q4 2014.
1,102 funds tracked by Wall St. Rank held Biogen as of Q1 2018.

Based on Duquesne Family Office's 13F filing for Q1 2018, filed 15 May 2018.